Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-12-03
2010-06-29
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S569000
Reexamination Certificate
active
07745431
ABSTRACT:
Pharmaceutical compositions comprising 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine; or a pharmaceutically acceptable salt thereof. The compositions are used for treating, preventing or delaying the onset of disorders mediated by LTB4, TXA2or adenosine.
REFERENCES:
patent: 3736315 (1973-05-01), Kórósi et al.
patent: 4025528 (1977-05-01), Maeda et al.
patent: RE30014 (1979-05-01), Korosi et al.
patent: 4322346 (1982-03-01), Kórósi et al.
patent: 4423044 (1983-12-01), Kórósi et al.
patent: 4614740 (1986-09-01), Láng et al.
patent: 4835152 (1989-05-01), Kórósi et al.
patent: 4840948 (1989-06-01), Láng et al.
patent: 5204343 (1993-04-01), Andrási et al.
patent: 5288863 (1994-02-01), Somogyi et al.
patent: 5457118 (1995-10-01), Dickinson et al.
patent: 5459137 (1995-10-01), Andrási et al.
patent: 5519019 (1996-05-01), Andrási et al.
patent: 5521174 (1996-05-01), Andrási et al.
patent: 5639751 (1997-06-01), Andrási et al.
patent: 5891871 (1999-04-01), Xia et al.
patent: 6075018 (2000-06-01), Vágó et al.
patent: 6080736 (2000-06-01), Landry
patent: 6291530 (2001-09-01), Greenspan et al.
patent: 6638928 (2003-10-01), Harris et al.
patent: 6649607 (2003-11-01), Leventer et al.
patent: 6683072 (2004-01-01), Kucharik et al.
patent: 6864251 (2005-03-01), Kucharik et al.
patent: 7022700 (2006-04-01), Harris et al.
patent: 7078398 (2006-07-01), Leventer et al.
patent: 2004/0138209 (2004-07-01), Kucharik et al.
patent: 2004/0138210 (2004-07-01), Harris et al.
patent: 2004/0152695 (2004-08-01), Harris et al.
patent: 2004/0157833 (2004-08-01), Harris et al.
patent: 2004/0162284 (2004-08-01), Harris et al.
patent: 2004/0224943 (2004-11-01), Leventer et al.
patent: 2004/0229866 (2004-11-01), Harris et al.
patent: 2004/0229867 (2004-11-01), Kucharik
patent: 2004/0254173 (2004-12-01), Leventer et al.
patent: 2005/0075329 (2005-04-01), Leventer et al.
patent: 2005/0288277 (2005-12-01), Kucharik et al.
patent: 2006/0166976 (2006-07-01), Leventer et al.
patent: 2007/0021412 (2007-01-01), Kucharik et al.
patent: 2007/0032479 (2007-02-01), Leventer et al.
patent: 492 485 (1992-07-01), None
patent: 178516 (1983-03-01), None
patent: 178519 (1983-03-01), None
patent: 92/11262 (1992-07-01), None
patent: 00/24400 (2000-05-01), None
patent: 02/094189 (2002-11-01), None
patent: WO 02/088096 (2002-11-01), None
Vermylen et al. “Thromboxane Synthase Inhibitors and Receptor Antagonists” 1992, Cardiovascular Drugs and Therapy, vol. 6, pp. 29-33.
Gomtsyan et al. “Nonnucleoside inhibitos of adenosine kinase”, 2004, Current Pharmaceutical Design, vol. 10, pp. 1093-1103.
Riccioni et al. “Brief Review: Advances in Therapy with Antileukotriene Drugs”, 2004, Annals of Clinicla and Laboratory Science, vol. 34, No. 4, pp. 379-387.
Terasaka, T. “Non-nucloeside adenosine deaminase inhibitors: 2000-2004”, Expert Opinion of Therapeutic Patents, Jul. 2005, vol. 15, No. 7, pp. 817-828.
F. Gatta et al., “Derivatives of 2,3-Benzodiazepine(*)”, Il Farmaco—Ed. Sc.—vol. 40—fasc. 12, pp. 942-955.
R. Sladká et al., “A Placebo-controlled Clinical Trial with Tofizopam * in the Treatment of Anxiety Neurosis” Divisions of Psychiatry, District Institutes of National Heatlth, Prague, 2 and 4; Psychiatric Department and Psychiatric Research Unity, Medical Scholl of Charles University, Prague, Czechoslovakia, pp. 176-180.
Edit J. Horváth et al., “Anxiolytic 2,3-benzodiazepines, their Specific Binding to the Basal Ganglia”, Progress in Neurobiology vol. 60 (2000), pp. 309-342.
E. Tomori et al., “Investigation of the Metabolites of Tofizopam in Man and Animals by Gas-Liquid Chromatography-Mass Spectrometry”, Journal of Chromatography, 241 (1982), pp. 89-99.
Eva Tomori et al., “Investigation of Metabolites of Tofizopam in Man and Animals”, Polish Journal of Parmacology and Pharmacy, 1984, 36, pp. 423-430., PL ISSN 0301-0214.
Sharon Pellow et al., “The Effects of Tofisopam, a 3,4-Benzodiazepine, in Animal Models of Anxiety, Sedation, and Convulsions”, Drug Development Research 7, pp. 61-73 (1986).
A. Bond et al., “A Comparison of the Psychotropic Profiles of Tofisopam and Diazepam”, Fur J Clin Pharmacol (1982) 22, pp. 137-142.
J. Kanto et al., “Tofizopam: A Benzodiazepine Derivative Without Sedative Effect”, International Journal of Clinical Pharmacology, Therapy and Toxicology, vol. 20 No. 7—1982, pp. 309-312.
T. Mennini et al., “Brain Levels of Tofizopam in the Rat and Relationship with Benzodiazepine Receptors”, Naunyn-Schmiedeberg's Arch Pharmacol (1982) 321, pp. 112-115.
K. Maier et al., “The Effect of Tofisopam on Psychic Performance in Persons with More than Average Anxiety: A Controlled Experimental Trial”, Current Therapeutic Research, vol. 35, No. 4, Apr. 1984, pp. 541-548.
Chihiro Ito, Behavioral Pharmacological Study of the Structure-Activity Relationship of Benzodiazepine Derivatives—with Particular Reference to the Activity of 2,3-Benzodiazepine-, (1981) 39(3), pp. 369-384 (Japanese), pp. 1-30 (English Translation).
Giovambattista De Sarro et al., “GYKI 52466 and Related 2,3-Benzodiazepines as Anticonvulsant Agents in DBA/2 Mice”, European Journal of Pharmacology 294 (1995), pp. 411-422.
T. Seppälä, “Tofisopam, A Novel 3,4-Benzodiazepine: Multiple-Dose Effects on Psychomotor Skills and Memory. Comparison with Diazepam and Interactions with Ethanol”, Psychopharmacology 69, (1980), pp. 209-218.
Veijo Saano et al., “Tofizopam Modulates the Affinity of Benzodiazepine Receptors in the Rat Brain”, Pharmacology Biochemistry & Behavior, vol. 17, (1982), pp. 367-369.
A. Pakkanen et al., “Comparative Study of the Clinical Effects of Tofizopam, Nitrazepam and Placebo as Oral Premedication”, British Journal of Anaesthesics, pp. 1009-1012.
V. Saano et al., “Tofizopam Enhances the Action of Diazepam Against Tremor and Convulsions”, Medical Biology 61: (1983), pp. 49-53.
V. Saano et al., “Tofizopam Selectively Increases the Action of Anticonvulsants”, Medical Biology, 64 (1986), pp. 201-206.
István Tarnawa et al., “Structure-Activity Relationships of 2,3-Benzodiazepine Compounds with Glutamate Antagonistic Action”, Bioorganic & Medical Chemistry Letters, vol. 3, No. 1, (1993), pp. 99-104.
K. Yamaguchi et al., PMID: 6136319, Abstract of “Tofisopam, A New 2,3-Benzodiazepine. Inhibition of Changes Induced by Stress Loading and Hypothalamic Stimulation”, Can. J. Physiol Pharmaco, vol. 61, (1983), pp. 619-625.
Szegó Judit et al., “Selected Passages From the Clinical-Pharmacological and Clinical Trials of Grandaxin®,”Acta Pharmaceutica Hungarica vol. 63, (1993), pp. 91-98 (Hungarian). pp. 1-10 (English Translation Provided).
L. Petócz et al., The Main Pharmacological Characteristics of Grandaxin (Tofizopam, Egyt-341), Hungarian Medical Journal, vol. 23, No. 4, (1975), pp. 134-138.
Petócz Luijza, “The Pharmacological Effects of Tofizopam (Grandaxin)®”, Acta Pharmaceutica Hungarica, vol. 63, (1993), pp. 79-82 (Hungarian. pp. 1-4 (English Translation Provided).
Study of efficacy and safety of Grandaxin tablets for unidentified complaints with digestive system disease. Asano Sadhiro, Orita Yuichi, Kuga Masafumi and Amamor Masanori. Journal of New Remedies & Clinics, 1993, vol. 42, No. 12, pp. 2551-2556. English translation provided.
Clinical Evaluation of Tofisopam (Grandaxin) on Gastro-intestinal Various Unidentified Complaints. Aoyagi Toshio, Kubo Akiyoshi, Sano Masaaki, Kashiwazaki Kazuo, Kojima Toshiya, Nishizato Yoshinori, Koizumi Kazumasa, Yoshioka Masahiro and Miyake Shozo. Japanese Pharmacology & Therapeutics, 1992, vol. 20, No. 2, pp. 657-667. English translation provided.
From actual practice o
Harris Herbert W.
Kucharik Robert F.
Leventer Steven M.
Carter Kendra D
Drinker Biddle & Reath LLP
Padmanabhan Sreeni
Vela Acquisition Corporation
LandOfFree
Pharmaceutical composition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical composition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4207851